The use of mannitol in partial and live donor nephrectomy: An international survey

M. Cosentino; A. Breda; F. Sanguedolce; J. Landman; J. U. Stolzenburg; P. Verze; J. Rassweiler; H. Van Poppel; H. C. Klingler; G. Janetschek; A. Celia; F. J. Kim; G. Thalmann; U. Nagele; A. Mogorovich; C. Bolenz; T. Knoll; F. Porpiglia; M. Alvarez-Maestro; F. Francesca; F. Deho; S. Eggener; C. Abbou; M. V. Meng; M. Aron; P. Laguna; D. Mladenov; A. D'Addessi; P. Bove; R. Schiavina; O. De Cobelli; A. S. Merseburger; O. Dalpiaz; F. C.H. D'Ancona; T. J. Polascik; R. Muschter; T. J. Leppert; H. Villavicencio

doi:10.1007/s00345-012-1003-1

The use of mannitol in partial and live donor nephrectomy: An international survey

M. Cosentino^*, A. Breda, F. Sanguedolce, J. Landman, J. U. Stolzenburg, P. Verze, J. Rassweiler, H. Van Poppel, H. C. Klingler, G. Janetschek, A. Celia, F. J. Kim, G. Thalmann, U. Nagele, A. Mogorovich, C. Bolenz, T. Knoll, F. Porpiglia, M. Alvarez-Maestro, F. FrancescaF. Deho, S. Eggener, C. Abbou, M. V. Meng, M. Aron, P. Laguna, D. Mladenov, A. D'Addessi, P. Bove, R. Schiavina, O. De Cobelli, A. S. Merseburger, O. Dalpiaz, F. C.H. D'Ancona, T. J. Polascik, R. Muschter, T. J. Leppert, H. Villavicencio

^*Corresponding author for this work

Clinic of Urology

26 Citations (Scopus)

Abstract

Purpose: Animal studies have shown the potential benefits of mannitol as renoprotective during warm ischemia; it may have antioxidant and anti-inflammatory properties and is sometimes used during partial nephrectomy (PN) and live donor nephrectomy (LDN). Despite this, a prospective study on mannitol has never been performed. The aim of this study is to document patterns of mannitol use during PN and LDN. Materials and methods: A survey on the use of mannitol during PN and LDN was sent to 92 high surgical volume urological centers. Questions included use of mannitol, indications for use, physician responsible for administration, dosage, timing and other renoprotective measures. Results: Mannitol was used in 78 and 64 % of centers performing PN and LDN, respectively. The indication for use was as antioxidant (21 %), as diuretic (5 %) and as a combination of the two (74 %). For PN, the most common dosages were 12.5 g (30 %) and 25 g (49 %). For LDN, the most common doses were 12.5 g (36.3 %) and 25 g (63.7 %). Overall, 83 % of centers utilized mannitol, and two (percent or centers??) utilized furosemide for renoprotection. Conclusions: A large majority of high-volume centers performing PN and LDN use mannitol for renoprotection. Since there are no data proving its value nor standardized indication and usage, this survey may provide information for a randomized prospective study.

Original language	English
Journal	World Journal of Urology
Volume	31
Issue number	4
Pages (from-to)	977-982
Number of pages	6
ISSN	0724-4983
DOIs	https://doi.org/10.1007/s00345-012-1003-1
Publication status	Published - 08.2013

Research Areas and Centers

Research Area: Luebeck Integrated Oncology Network (LION)

Access to Document

10.1007/s00345-012-1003-1

Cite this

Cosentino, M., Breda, A., Sanguedolce, F., Landman, J., Stolzenburg, J. U., Verze, P., Rassweiler, J., Van Poppel, H., Klingler, H. C., Janetschek, G., Celia, A., Kim, F. J., Thalmann, G., Nagele, U., Mogorovich, A., Bolenz, C., Knoll, T., Porpiglia, F., Alvarez-Maestro, M., ... Villavicencio, H. (2013). The use of mannitol in partial and live donor nephrectomy: An international survey. World Journal of Urology, 31(4), 977-982. https://doi.org/10.1007/s00345-012-1003-1

@article{ea44bb2edec4455a8e721099ca6d86de,

title = "The use of mannitol in partial and live donor nephrectomy: An international survey",

abstract = "Purpose: Animal studies have shown the potential benefits of mannitol as renoprotective during warm ischemia; it may have antioxidant and anti-inflammatory properties and is sometimes used during partial nephrectomy (PN) and live donor nephrectomy (LDN). Despite this, a prospective study on mannitol has never been performed. The aim of this study is to document patterns of mannitol use during PN and LDN. Materials and methods: A survey on the use of mannitol during PN and LDN was sent to 92 high surgical volume urological centers. Questions included use of mannitol, indications for use, physician responsible for administration, dosage, timing and other renoprotective measures. Results: Mannitol was used in 78 and 64 % of centers performing PN and LDN, respectively. The indication for use was as antioxidant (21 %), as diuretic (5 %) and as a combination of the two (74 %). For PN, the most common dosages were 12.5 g (30 %) and 25 g (49 %). For LDN, the most common doses were 12.5 g (36.3 %) and 25 g (63.7 %). Overall, 83 % of centers utilized mannitol, and two (percent or centers??) utilized furosemide for renoprotection. Conclusions: A large majority of high-volume centers performing PN and LDN use mannitol for renoprotection. Since there are no data proving its value nor standardized indication and usage, this survey may provide information for a randomized prospective study.",

author = "M. Cosentino and A. Breda and F. Sanguedolce and J. Landman and Stolzenburg, {J. U.} and P. Verze and J. Rassweiler and {Van Poppel}, H. and Klingler, {H. C.} and G. Janetschek and A. Celia and Kim, {F. J.} and G. Thalmann and U. Nagele and A. Mogorovich and C. Bolenz and T. Knoll and F. Porpiglia and M. Alvarez-Maestro and F. Francesca and F. Deho and S. Eggener and C. Abbou and Meng, {M. V.} and M. Aron and P. Laguna and D. Mladenov and A. D'Addessi and P. Bove and R. Schiavina and {De Cobelli}, O. and Merseburger, {A. S.} and O. Dalpiaz and D'Ancona, {F. C.H.} and Polascik, {T. J.} and R. Muschter and Leppert, {T. J.} and H. Villavicencio",

year = "2013",

month = aug,

doi = "10.1007/s00345-012-1003-1",

language = "English",

volume = "31",

pages = "977--982",

journal = "World Journal of Urology",

issn = "0724-4983",

number = "4",

}

Cosentino, M, Breda, A, Sanguedolce, F, Landman, J, Stolzenburg, JU, Verze, P, Rassweiler, J, Van Poppel, H, Klingler, HC, Janetschek, G, Celia, A, Kim, FJ, Thalmann, G, Nagele, U, Mogorovich, A, Bolenz, C, Knoll, T, Porpiglia, F, Alvarez-Maestro, M, Francesca, F, Deho, F, Eggener, S, Abbou, C, Meng, MV, Aron, M, Laguna, P, Mladenov, D, D'Addessi, A, Bove, P, Schiavina, R, De Cobelli, O, Merseburger, AS, Dalpiaz, O, D'Ancona, FCH, Polascik, TJ, Muschter, R, Leppert, TJ & Villavicencio, H 2013, 'The use of mannitol in partial and live donor nephrectomy: An international survey', World Journal of Urology, vol. 31, no. 4, pp. 977-982. https://doi.org/10.1007/s00345-012-1003-1

TY - JOUR

T1 - The use of mannitol in partial and live donor nephrectomy: An international survey

AU - Cosentino, M.

AU - Breda, A.

AU - Sanguedolce, F.

AU - Landman, J.

AU - Stolzenburg, J. U.

AU - Verze, P.

AU - Rassweiler, J.

AU - Van Poppel, H.

AU - Klingler, H. C.

AU - Janetschek, G.

AU - Celia, A.

AU - Kim, F. J.

AU - Thalmann, G.

AU - Nagele, U.

AU - Mogorovich, A.

AU - Bolenz, C.

AU - Knoll, T.

AU - Porpiglia, F.

AU - Alvarez-Maestro, M.

AU - Francesca, F.

AU - Deho, F.

AU - Eggener, S.

AU - Abbou, C.

AU - Meng, M. V.

AU - Aron, M.

AU - Laguna, P.

AU - Mladenov, D.

AU - D'Addessi, A.

AU - Bove, P.

AU - Schiavina, R.

AU - De Cobelli, O.

AU - Merseburger, A. S.

AU - Dalpiaz, O.

AU - D'Ancona, F. C.H.

AU - Polascik, T. J.

AU - Muschter, R.

AU - Leppert, T. J.

AU - Villavicencio, H.

PY - 2013/8

Y1 - 2013/8

N2 - Purpose: Animal studies have shown the potential benefits of mannitol as renoprotective during warm ischemia; it may have antioxidant and anti-inflammatory properties and is sometimes used during partial nephrectomy (PN) and live donor nephrectomy (LDN). Despite this, a prospective study on mannitol has never been performed. The aim of this study is to document patterns of mannitol use during PN and LDN. Materials and methods: A survey on the use of mannitol during PN and LDN was sent to 92 high surgical volume urological centers. Questions included use of mannitol, indications for use, physician responsible for administration, dosage, timing and other renoprotective measures. Results: Mannitol was used in 78 and 64 % of centers performing PN and LDN, respectively. The indication for use was as antioxidant (21 %), as diuretic (5 %) and as a combination of the two (74 %). For PN, the most common dosages were 12.5 g (30 %) and 25 g (49 %). For LDN, the most common doses were 12.5 g (36.3 %) and 25 g (63.7 %). Overall, 83 % of centers utilized mannitol, and two (percent or centers??) utilized furosemide for renoprotection. Conclusions: A large majority of high-volume centers performing PN and LDN use mannitol for renoprotection. Since there are no data proving its value nor standardized indication and usage, this survey may provide information for a randomized prospective study.

AB - Purpose: Animal studies have shown the potential benefits of mannitol as renoprotective during warm ischemia; it may have antioxidant and anti-inflammatory properties and is sometimes used during partial nephrectomy (PN) and live donor nephrectomy (LDN). Despite this, a prospective study on mannitol has never been performed. The aim of this study is to document patterns of mannitol use during PN and LDN. Materials and methods: A survey on the use of mannitol during PN and LDN was sent to 92 high surgical volume urological centers. Questions included use of mannitol, indications for use, physician responsible for administration, dosage, timing and other renoprotective measures. Results: Mannitol was used in 78 and 64 % of centers performing PN and LDN, respectively. The indication for use was as antioxidant (21 %), as diuretic (5 %) and as a combination of the two (74 %). For PN, the most common dosages were 12.5 g (30 %) and 25 g (49 %). For LDN, the most common doses were 12.5 g (36.3 %) and 25 g (63.7 %). Overall, 83 % of centers utilized mannitol, and two (percent or centers??) utilized furosemide for renoprotection. Conclusions: A large majority of high-volume centers performing PN and LDN use mannitol for renoprotection. Since there are no data proving its value nor standardized indication and usage, this survey may provide information for a randomized prospective study.

UR - http://www.scopus.com/inward/record.url?scp=84881034952&partnerID=8YFLogxK

U2 - 10.1007/s00345-012-1003-1

DO - 10.1007/s00345-012-1003-1

M3 - Journal articles

C2 - 23242033

AN - SCOPUS:84881034952

VL - 31

SP - 977

EP - 982

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 4

ER -

The use of mannitol in partial and live donor nephrectomy: An international survey

Abstract

Research Areas and Centers

Access to Document

Other files and links

Fingerprint

Cite this